Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)

A Phase 2a Study of Daclatasvir in Combination With Peginterferon Alfa-2a(Pegasys®) and Ribavirin (Copegus®) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

The purpose of this study is to identify at least 1 dose of Daclatasvir, that when combined with peginterferon-alfa (PegIFNα) and ribavirin (RBV) for the treatment of chronically infected HCV genotype 1 treatment-naïve and non-responder to standard of care subjects is safe, well tolerated, and efficacious

Key Inclusion Criteria:

• Subjects chronically infected with hepatitis C virus (HCV) genotype 1
• HCV RNA viral load ≥ 10*5* IU/mL (100,000 IU/mL) at screening
• The current standard of care naïve or non-responder

Key Exclusion Criteria:

• Cirrhosis
• HCC
• Co-infection with hepatitis B virus (HBV), HIV-1 or HIV-2